eligibility_summary
Adults with RRMM eligible for teclistamab: ≥3 prior lines (PI, IMiD, anti‑CD38), progressed on last, treated at specified centers, consent, caregiver, adequate labs, frailty ≤5, contraception. Exclude prior BCMA/teclistamab, unresolved tox, CNS/EMD/plasma cell leukemia/rapid disease, key infections/comorbidities, serious cardiac disease/recent surgery, or other conditions interfering. Caregivers: ≥18, English, consent, training, transport, near‑continuous support to Day 27, monitor/report.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
NCT06251076 tests outpatient step-up dosing of teclistamab for relapsed/refractory multiple myeloma, with or without prophylactic tocilizumab. Drugs/mechanisms: 1) Teclistamab—bispecific T‑cell–engaging antibody (BiTE) that binds CD3 on T cells and BCMA on myeloma plasma cells, redirecting cytotoxic T cells to kill BCMA+ cells. 2) Tocilizumab—monoclonal antibody IL‑6 receptor inhibitor, used prophylactically to blunt cytokine release syndrome. Targets/pathways: CD3+ T cells (activation/redirection), BCMA on malignant plasma cells, and the IL‑6/IL‑6R signaling pathway (CRS mitigation). Arms: teclistamab per label, teclistamab plus one prophylactic tocilizumab before step‑up dose 1, community rollout using the best method from earlier cohorts, caregiver cohort for burden assessment.